NeuBase Total Current Assets vs Capital Surpluse Analysis
NBSE Stock | USD 0.44 0.02 4.76% |
NeuBase Therapeutics financial indicator trend analysis is infinitely more than just investigating NeuBase Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NeuBase Therapeutics is a good investment. Please check the relationship between NeuBase Therapeutics Total Current Assets and its Capital Surpluse accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeuBase Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. For information on how to trade NeuBase Stock refer to our How to Trade NeuBase Stock guide.
Total Current Assets vs Capital Surpluse
Total Current Assets vs Capital Surpluse Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NeuBase Therapeutics Total Current Assets account and Capital Surpluse. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between NeuBase Therapeutics' Total Current Assets and Capital Surpluse is -0.5. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Capital Surpluse in the same time period over historical financial statements of NeuBase Therapeutics, assuming nothing else is changed. The correlation between historical values of NeuBase Therapeutics' Total Current Assets and Capital Surpluse is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of NeuBase Therapeutics are associated (or correlated) with its Capital Surpluse. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Surpluse has no effect on the direction of Total Current Assets i.e., NeuBase Therapeutics' Total Current Assets and Capital Surpluse go up and down completely randomly.
Correlation Coefficient | -0.5 |
Relationship Direction | Negative |
Relationship Strength | Very Weak |
Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Capital Surpluse
Most indicators from NeuBase Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NeuBase Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeuBase Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. For information on how to trade NeuBase Stock refer to our How to Trade NeuBase Stock guide.At present, NeuBase Therapeutics' Enterprise Value Over EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 0.22, whereas Sales General And Administrative To Revenue is forecasted to decline to 0.17.
2020 | 2021 | 2023 | 2024 (projected) | Cost Of Revenue | 575.5K | 1.3M | 1.1M | 1.1M | Research Development | 14.4M | 21.4M | 19.3M | 18.3M |
NeuBase Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
NeuBase Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
NeuBase Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 12.5M | 34.4M | 64.2M | 32.7M | 37.6M | 39.5M | |
Short Long Term Debt Total | 122.9K | 138.6K | 6.5M | 6.0M | 6.9M | 7.2M | |
Other Current Liab | 496.3K | 950.2K | 1.7M | 1.7M | 1.9M | 2.0M | |
Total Current Liabilities | 2.5M | 3.1M | 4.2M | 4.2M | 4.8M | 5.0M | |
Total Stockholder Equity | 10.0M | 31.3M | 54.1M | 23.2M | 26.7M | 14.0M | |
Property Plant And Equipment Net | 431.0K | 1.2M | 8.4M | 7.8M | 8.9M | 9.4M | |
Net Debt | (10.2M) | (31.9M) | (46.4M) | (17.2M) | (19.7M) | (20.7M) | |
Retained Earnings | (27.0M) | (43.6M) | (69.0M) | (102.7M) | (92.5M) | (87.8M) | |
Non Current Assets Total | 1.5M | 1.6M | 9.2M | 8.0M | 9.3M | 5.5M | |
Non Currrent Assets Other | 338.9K | 145.3K | 414.0K | 273.2K | 314.2K | 298.5K | |
Cash And Short Term Investments | 10.3M | 32.0M | 52.9M | 23.2M | 26.6M | 28.0M | |
Common Stock Shares Outstanding | 413.6K | 981.0K | 1.4M | 1.6M | 1.9M | 2.0M | |
Liabilities And Stockholders Equity | 12.5M | 34.4M | 64.2M | 32.7M | 37.6M | 39.5M | |
Non Current Liabilities Total | 1.6M | 1.6M | 5.9M | 5.3M | 6.1M | 6.4M | |
Other Stockholder Equity | 37.0M | 74.9M | 123.0M | 125.9M | 144.8M | 152.1M | |
Total Liab | 2.5M | 3.1M | 10.1M | 9.5M | 10.9M | 11.5M | |
Property Plant And Equipment Gross | 431.0K | 1.2M | 8.9M | 9.1M | 10.4M | 10.9M | |
Total Current Assets | 11.0M | 32.8M | 54.9M | 24.6M | 28.3M | 29.8M | |
Short Term Debt | 122.9K | 138.6K | 638.6K | 660.7K | 759.8K | 797.8K | |
Common Stock | 1.7K | 2.3K | 3.3K | 3.3K | 3.0K | 2.8K | |
Accounts Payable | 1.5M | 1.5M | 1.8M | 1.8M | 1.7M | 1.6M | |
Cash | 10.3M | 32.0M | 52.9M | 23.2M | 20.8M | 19.8M | |
Other Current Assets | 265.7K | 294.6K | 2.0B | 1.5M | 1.7M | 1.6M | |
Net Tangible Assets | 9.9M | 31.3M | 54.1M | 23.2M | 26.7M | 22.1M | |
Property Plant Equipment | 431.0K | 1.2M | 8.4M | 7.8M | 8.9M | 9.4M | |
Short Long Term Debt | 73.2K | 122.9K | 138.6K | 148.4K | 170.6K | 124.2K | |
Net Invested Capital | 10.2M | 31.4M | 54.2M | 23.2M | 26.7M | 28.0M | |
Net Working Capital | 8.5M | 29.7M | 50.7M | 20.5M | 23.6M | 22.1M | |
Capital Stock | 1.7K | 2.3K | 3.3K | 3.3K | 3.0K | 2.6K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeuBase Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. For information on how to trade NeuBase Stock refer to our How to Trade NeuBase Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Complementary Tools for NeuBase Stock analysis
When running NeuBase Therapeutics' price analysis, check to measure NeuBase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuBase Therapeutics is operating at the current time. Most of NeuBase Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuBase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuBase Therapeutics' price. Additionally, you may evaluate how the addition of NeuBase Therapeutics to your portfolios can decrease your overall portfolio volatility.
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |
Is NeuBase Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeuBase Therapeutics. If investors know NeuBase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeuBase Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (18.60) | Return On Assets (0.43) | Return On Equity (0.93) |
The market value of NeuBase Therapeutics is measured differently than its book value, which is the value of NeuBase that is recorded on the company's balance sheet. Investors also form their own opinion of NeuBase Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is NeuBase Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeuBase Therapeutics' market value can be influenced by many factors that don't directly affect NeuBase Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeuBase Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeuBase Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeuBase Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.